Loading company
Aldeyra Therapeutics, Inc.
ALDX · Nasdaq · ·
Next earnings: November 4, 2026
$1.32+12.8%Sep 29 close
- 1M
- -11.1%
- 6M
- -21.4%
- 1Y
- -74.7%
- 5Y
- -84.9%
ALDX · Nasdaq · ·
Next earnings: November 4, 2026
$1.32+12.8%Sep 29 close
Aldeyra Therapeutics, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$5.5M | -$9.8M | +44.20% |
| Profit per share | -$0.09 | -$0.16 | +43.75% |
| Free Cash Flow | $500.4K | -$11.2M | +104.46% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Aldeyra Therapeutics, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX‑629, ADX‑246, ADX‑248, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease (under U.S. Food and Drug Administration New Drug Application Review) and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma (under U.S. Food and Drug Administration New Drug Application Priority Review), proliferative vitreoretinopathy, and other rare sight-threatening retinal diseases.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Aldeyra Therapeutics, Inc.’s Item 2.02 8-K filed May 4, 2023; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.